Back to Search Start Over

PCN127 Cost per Outcome Analysis of Nivolumab Versus Dabrafenib+Trametinib As Adjuvant Therapy for Patients with STAGE Iiib/C BRAF-Mutant Cutaneous Melanoma in Spain.

Authors :
Polanco Sánchez, C.
Moshyk, A.
Amadi, A.
Poretta, T.
Galan, J.
Vembusubramanian, M.
Betts, K.A.
Du, E.X.
Source :
Value in Health. 2020 Supplement 2, Vol. 23, pS445-S445. 1p.
Publication Year :
2020

Subjects

Subjects :
*NIVOLUMAB
*MELANOMA
*COST

Details

Language :
English
ISSN :
10983015
Volume :
23
Database :
Academic Search Index
Journal :
Value in Health
Publication Type :
Academic Journal
Accession number :
160979882
Full Text :
https://doi.org/10.1016/j.jval.2020.08.264
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details